Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination ...

After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...

Pfizer’s chief strategist Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 ...

Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that can cause muscle weakness, fatigue and problems ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

Biovac has secured a $108.3 million financing package that will allow the South African pharma company to build the continent ...

In a blow to Bayer, a U.S. federal judge in Manhattan has said he will not block Johnson & Johnson’s survival claims on a key ...

Theramex has opted out of the U.K.’s self-regulatory program for pharma ma | Theramex has opted out of the U.K.’s ...

Genentech has launched the “Life Doesn’t Wait” campaign to mark World Hemophilia Day, dialing up its focus on patient stories ...